Stephen Michael Kelsey, who serves as President of Research and Development at Revolution Medicines, Inc. (NASDAQ:RVMD), sold 4,302 shares of the company’s common stock on March 17, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The sale was executed at a per-share price of $99.4804, producing total proceeds of $427,964. The transaction was carried out under a Rule 10b5-1 trading plan that Kelsey adopted on May 31, 2023. The filing states the plan was used to satisfy tax obligations stemming from the vesting of restricted stock units.
After the disposition, Kelsey is recorded as having direct ownership of 295,398 shares of Revolution Medicines, which includes 84,250 restricted stock units. The insider sale occurred while RVMD shares are trading close to a 52-week high of $124.49, following a 156% return over the prior 12 months.
Market analysis noted alongside the filing includes an InvestingPro assessment that the stock appears fairly valued at current levels. Investors seeking more comprehensive data are directed to a Pro Research Report that covers Revolution Medicines as well as over 1,400 other U.S. equities.
Revolution Medicines also released its fourth-quarter 2025 results, reporting a net loss of $1.86 per share, wider than the consensus estimate of a negative $1.58 per share. The company attributed the shortfall to higher-than-expected research and development expenses and increased selling, general, and administrative costs.
At quarter end, Revolution Medicines reported $2.03 billion in cash and investments, a balance that the company said was supported in part by a strategic partnership with Royalty Pharma.
Analyst reaction has been mixed but generally constructive:
- UBS initiated coverage with a Buy rating, calling attention to the potential of the company’s RAS inhibitors across several solid tumor indications.
- Piper Sandler raised its price target on Revolution shares to $120 and maintained an Overweight rating, citing the company’s earnings report and updates to its development plan.
- Needham adjusted its price target slightly lower to $145 while keeping a Buy rating, pointing to increased costs as a consideration.
- Wells Fargo raised its price target to $144, citing confidence in trial progress and the company’s potential in treating pancreatic ductal adenocarcinoma.
Together, these analyst moves and the insider transaction paint a picture of both endorsement and caution among market observers regarding Revolution Medicines’ near-term trajectory. The combination of an insider sale tied to tax obligations, a wider-than-expected quarterly loss, a sizeable cash position, and several analyst updates underscores the multiple dynamics investors are weighing.
Clear summary
Stephen Michael Kelsey sold 4,302 Revolution Medicines shares on March 17, 2026 for $427,964 under a Rule 10b5-1 plan adopted in May 2023 to satisfy RSU-related tax obligations. The company reported a Q4 2025 net loss of $1.86 per share, driven by elevated R&D and SG&A expenses, and held $2.03 billion in cash and investments. Analyst responses range from new coverage with Buy ratings to adjusted price targets.
Key points
- An insider sale of 4,302 shares generated $427,964 and was executed under a preexisting Rule 10b5-1 plan tied to restricted stock unit vesting.
- Revolution Medicines reported a Q4 2025 net loss per share of $1.86, wider than the consensus estimate of negative $1.58, due to higher R&D and SG&A spending.
- Analysts responded with a mix of Buy initiations and price-target adjustments; the company ended the quarter with $2.03 billion in cash and investments supported by a partnership with Royalty Pharma.
Risks and uncertainties
- Elevated research and development expenses and higher selling, general, and administrative costs contributed to an earnings shortfall, creating near-term financial pressure.
- The company reported a net loss per share larger than consensus expectations for Q4 2025, reflecting quarterly performance below analyst estimates.
- RVMD shares are trading near a 52-week high after a 156% gain over the past year, a backdrop that may influence investor sentiment and valuation assessments.